Skip to main content
. 2022 Jan 1;18(2):507–521. doi: 10.7150/ijbs.67770

Figure 6.

Figure 6

HPV16 E6/E7 and IGF2BP2 enhance CC tumor growth in vivo. (A, B) SiHa cells stably expressing shHPV16 E6/E7, shIGF2BP2, shHPV16 E6/E7+oe-IGF2BP2, or shNC were subcutaneously injected into the right flank of nude mice. Tumor images were acquired using the PerkinElmer IVIS preclinical in vivo imaging system 20 days (A) and 30 days (B) after injection. (C) From day 7 after injection, the tumor volume was measured every two days. (D) The weight of the xenografted tumors was measured. (E) Tumor sections underwent IHC staining using antibodies against Ki-67. Scale bars: 50 µm. (F) Kaplan-Meier survival curve showing the overall survival rate of mice in each group (n=7, *p < 0.05 by log-rank test). (G) Representative image of TUNEL staining, green indicates TUNEL-positive cells. Scale bars: 150 µm. (H) A proposed regulatory model of the role of IGF2BP2 in glycolysis and tumorigenesis. Each value represents the mean ± SD (Student's t test). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.